The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

NEWTON, MA, USA I 12, 2025 I Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and ...

Despite being one of the most effective cholesterol-lowering agents, statins remain a controversial topic in healthcare. This ...

BACKGROUND Guillain-Barre syndrome (GBS) commonly presents with motor weakness and neurological symptoms and signs that include loss of tendon reflexes. However, patients with GBS also experience ...

Autoimmune disorders in children can cause symptoms often mistaken for common childhood illnesses. More precise diagnoses and ...

Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

“Dermatomyositis is a chronic systemic autoimmune disease characterized by distinctive cutaneous eruptions, muscle weakness and other systemic manifestations including interstitial lung disease ...

Her current research focuses on the mechanisms of muscle disease in scleroderma and developing novel therapeutics for refractory dermatomyositis. She has led investigations on JAK inhibitor ...